Copied
 
 
2023,
21.03.2024
Bruttoresultat
Na.
Primær drift
Na.
Årets resultat
Na.
Aktiver
Na.
Kortfristede aktiver
Na.
Egenkapital
Na.
Afkastningsgrad

0 %

Soliditetsgrad

0 %

Likviditetsgrad

0 %

Resultat
21.03.2024
Årsrapport
2023
21.03.2024
2022
03.04.2023
2021
04.05.2022
2019
08.04.2020
2018
29.04.2019
2017
20.04.2018
2016
11.04.2017
2015
26.04.2016
Nettoomsætning41.333.00037.977.000139.775.000234.778.000187.677.000
Resultat af primær drift000-587.942.000652.390.000-246.384.000-115.646.000-81.327.000
Indtægter af kapitalandele (tilknyttede og associerede) 000
Finansielle indtægter00014.655.0009.988.0002.122.000592.0003.889.000
Finansieringsomkostninger000-3.390.000-37.322.000-33.509.000-44.356.000-42.394.000
Andre finansielle omkostninger000
Resultat før skat000-576.677.000625.056.000-277.771.000-159.410.000-119.832.000
Resultat000-571.541.000581.282.000-272.271.000-153.910.000-113.957.000
Forslag til udbytte000
Aktiver
21.03.2024
Årsrapport
2023
21.03.2024
2022
03.04.2023
2021
04.05.2022
2019
08.04.2020
2018
29.04.2019
2017
20.04.2018
2016
11.04.2017
2015
26.04.2016
Kortfristede varebeholdninger00000000
Kortfristede tilgodehavender fra salg og tjenesteydelser 000751.0003.274.00021.632.00011.510.000313.000
Likvider0001.081.060.000860.635.000588.718.000323.330.000440.199.000
Kortfristede aktiver0001.427.050.0001.178.823.000703.193.000373.173.000163.389.000
Immaterielle aktiver og goodwill00000000
Finansielle anlægsaktiver000
Materielle aktiver00000000
Langfristede aktiver000172.464.00050.974.00034.045.000321.453.00019.499.000
Aktiver0001.599.514.0001.229.797.000737.238.000694.626.000182.888.000
Aktiver
21.03.2024
Passiver
21.03.2024
Årsrapport
2023
21.03.2024
2022
03.04.2023
2021
04.05.2022
2019
08.04.2020
2018
29.04.2019
2017
20.04.2018
2016
11.04.2017
2015
26.04.2016
Forslag til udbytte000
Egenkapital0001.242.673.0001.116.281.000528.468.000278.194.000141.824.000
Hensatte forpligtelser000
Langfristet gæld til banker000
Anden langfristet gæld00
Langfristede forpligtelser161.707.0000132.986.000328.878.0000
Kortfristede forpligtelser195.134.000113.516.00075.784.00087.554.00041.064.000
Leverandører af varer og tjenesteydelser000
Kortfristede forpligtelser000
Gældsforpligtelser000
Forpligtelser000356.841.000113.516.000208.770.000416.432.00041.064.000
Passiver0001.599.514.0001.229.797.000737.238.000694.626.000182.888.000
Passiver
21.03.2024
Nøgletal
21.03.2024
Årsrapport
2023
21.03.2024
2022
03.04.2023
2021
04.05.2022
2019
08.04.2020
2018
29.04.2019
2017
20.04.2018
2016
11.04.2017
2015
26.04.2016
Afkastningsgrad Na.Na.Na.-36,8 %53,0 %-33,4 %-16,6 %-44,5 %
Dækningsgrad
Resultatgrad Na.Na.Na.Na.Na.Na.Na.Na.
Varelagerets omsætningshastighed Na.Na.Na.Na.Na.Na.Na.Na.
Egenkapitals-forretning Na.Na.Na.-46,0 %52,1 %-51,5 %-55,3 %-80,4 %
Payout-ratio Na.Na.Na.
Gældsdæknings-nøgletal Na.Na.Na.-17.343,4 %1.748,0 %-735,3 %-260,7 %-191,8 %
Soliditestgrad Na.Na.Na.77,7 %90,8 %71,7 %40,0 %77,5 %
Likviditetsgrad Na.Na.Na.
Resultat
21.03.2024
Gæld
21.03.2024
Årsrapport
21.03.2024
Nyeste:01.01.2023- 31.12.2023(offentliggjort: 21.03.2024)
Beretning
21.03.2024
Dato for ledelsens godkendelse af årsrapporten:2024-02-27
Ledelsespåtegning:Statement of the Board of Directors and Executive ManagementThe Board of Directors and Executive Management have today discussed and approved the Annual Report of Zealand Pharma A/S for the financial year January 1 – December 31, 2023. The consolidated financial statements and parent company financial statements have been prepared in accordance with IFRS Accounting Standards as adopted by the EU and additional requirements under the Danish Financial Statements Act. We consider the accounting policies used to be appropriate. In our opinion, the consolidated financial statements and parent company financial statements give a true and fair view of the Group’s and the parent company’s financial position as of December 31, 2023, and of the results of the Group’s and the parent company’s operations and cash flows for the financial year January 1 – December 31, 2023. In our opinion, the Management’s review includes a fair review of the development of the Group’s and the parent company’s oper-ations and economic conditions, the results for the year, and the Group’s and the parent company’s financial position, as well as a review of the principal risks and uncertainties to which the Group and the parent company are exposed. In our opinion, the Annual Report of Zealand Pharma A/S for the financial year January 1 - December 31, 2023 identified as 549300ITBB1ULBL4CZ12-2023-12-31-en. zip has in all material respects been prepared in compliance with the ESEF Regulation. We recommend that the Annual Report be approved at the Annual General Meeting.